US Patent 11338013 Combination therapy for C3 inhibition

Patent 11338013 was granted and assigned to Apellis Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.

Is a

Current Assignee

Patent Jurisdiction

Patent Number

Date of Patent

May 24, 2022

Patent Application Number

16342477

Date Filed

October 16, 2017

Patent Citations Received

Patent Primary Examiner

In some aspects, the present invention provides certain combination therapies comprising compstatin analogs.

No Timeline data yet.

Title

Author

Link

Type

Date

No Further Resources data yet.

Find more entities like US Patent 11338013 Combination therapy for C3 inhibition

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

By using this site, you agree to our Terms of Service.